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ORIGINAL ARTICLE

Delay in diagnosis of patients with
head-and-neck cancer in Canada:
impact of patient and provider delay
S. Kassirian md,* A. Dzioba phd,† S. Hamel md,† K. Patel md,‡ A. Sahovaler md,†
D.A. Palma md msc phd,§ N. Read md,§ V. Venkatesan dlo,§ A.C. Nichols md,†
J. Yoo md,† K. Fung md,† A. Mendez md,† and S.D. MacNeil md msc†

ABSTRACT
Background Head-and-neck cancers (hncs) often present at an advanced stage, leading to poor outcomes. Late
presentation might be attributable to patient delays (reluctance to seek treatment, for instance) or provider delays
(misdiagnosis, prolonged wait time for consultation, for example). The objective of the present study was to examine
the length and cause of such delays in a Canadian universal health care setting.

Methods

Patients presenting for the first time to the hnc multidisciplinary team (mdt) with a biopsy-proven hnc
were recruited to this study. Patients completed a survey querying initial symptom presentation, their previous
medical appointments, and length of time between appointments. Clinical and demographic data were collected
for all patients.

Results The average time for patients to have their first appointment at the mdt clinic was 15.1 months, consisting
of 3.9 months for patients to see a health care provider ( hcp) for the first time since symptom onset and 10.7 months
from first hcp appointment to the mdt clinic. Patients saw an average of 3 hcps before the mdt clinic visit (range: 1–7).
No significant differences in time to presentation were found based on stage at presentation or anatomic site.

Conclusions At our tertiary care cancer centre, a patient’s clinical pathway to being seen at the mdt clinic shows
significant delays, particularly in the time from the first hcp visit to mdt referral. Possible methods to mitigate delay
include education about hnc for patients and providers alike, and a more streamlined referral system.

Key Words Delay in presentation, head-and-neck cancer, patient-reported outcomes
Curr Oncol. 2020 October27(5)e467–e477

INTRODUCTION
In 2019, head-and-neck cancers ( hncs ) had a projected
incidence of approximately 6500 new cases in Canada,
with approximately 1800 related deaths1. The modality of
treatment is site- and stage-dependent, but hnc is managed
largely with surgery or radiation, or both 2. Tumour stage
at presentation is one of the most significant prognostic
factors for hnc outcome3. Delays in treatment initiation
have been well-documented to result in advanced clinical
presentation4–8. However, the impact of delay in diagnosis on survival and quality-of-life outcomes is less well
known9,10. Presumably, patients who experience a delay in
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diagnosis present with more advanced-stage cancer and
experience poor outcomes; however, such a link has not
been established.
In Ontario, a substantial effort has been made to reduce wait times for patients with hnc once a referral is made
to a head-and-neck oncologist. Referrals are received from
a variety of sources, including general otolaryngologists,
dentists, oral surgeons, and general practitioners. Wait
times to consultation and then from initial consultation to
treatment are tracked, and efforts are ongoing at all major
head-and-neck institutions to reduce wait times. As of
January 2020 in Ontario, 89% of patients are seen for a first
hnc surgical appointment within the target time, and 70%
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of patients are treated within the target time from decision
to cancer surgery11. Similar data have been reported for hnc
radiation wait times12. Although the quality improvement
process has been a success, studies suggest that a much
more significant delay occurs before the initial consultation with a head-and-neck oncologist, with many patients
reporting multiple referrals, misdiagnoses, prolonged wait
times for biopsies and imaging, and lack of awareness on
the part of both the provider and the patient about the signs
and symptoms of hnc13,14.
The delay before assessment by a head-and-neck
oncologist can be divided into two main phases: patient
delay and provider delay. Patient delay results when individuals do not immediately seek medical attention for a new
symptom and is defined as the time from first symptom to
first visit with a health care provider ( hcp). Provider delay
occurs once the patient has made initial contact with the
first hcp for a symptom and is defined here as the time from
the visit with the hcp by the patient to the time of presentation at the multidisciplinary team (mdt) clinic. The
total length of patient and provider delay has been poorly
studied to date, and the causes for the component delays
are largely unknown.
In the present study, we sought to determine, for a
prospective cohort of consecutive new patients with hnc,
the lengths and causes of delay until presentation to the
head-and-neck oncologist (mdt clinic) at our high-volume
hnc centre. We hypothesized that a significant proportion
of the delay in presentation to the head-and-neck mdt clinic
would result from provider delay and multiple hcp referrals.

METHODS
Inclusion Criteria
All new adult patients with hnc presenting to the headand-neck cancer mdt clinic at the London Regional Cancer
Program from September 2017 to September 2018 were eligible for inclusion. The London Regional Cancer Program,
which services Southwestern Ontario, sees approximately
400 new patients with hnc per year. All patients presenting
to the head-and-neck mdt clinic must have a biopsy-proven
diagnosis of cancer. With few exceptions, once a referral is made to the head-and-neck mdt, patients are seen
within 2 weeks in the clinic, with most being seen in less
than 1 week. Patients are assessed by a head-and-neck surgical oncologist, a head-and-neck radiation oncologist, and
other members of the mdt. We recruited all new adult patients who were able to read and write in English, excluding
patients with recurrent cancer and patients with non-hncs.

Survey Development
A survey was developed based on a previously validated
Cancer Symptom Interval Measure questionnaire targeted
for patients with malignancy (Table i)15. The questionnaire
queried patients about presenting symptoms, the timing
of initial symptoms or signs, the time of first visit with a
hcp, and the number of health care visits before referral
to the head-and-neck mdt clinic. Patient demographics—including age, sex, history of smoking, alcohol use,
education, employment, and place of residence—were
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also requested. The survey was distributed in hard copy.
The Research Ethics Board at Western University approved
the study (no. 109197). All patients who participated in the
study signed a written consent form.

Data Collection
All new consecutive patients with hnc who presented to
the head-and-neck mdt were invited to participate in the
study. Patients were approached at the time of their initial
consultation at the clinic. A diagnosis of cancer had been
delivered, but in some cases, patients were not aware of the
treatment that they would receive. The study coordinator
obtained consent and administered the study questionnaire. Although the survey was self-administered, given
the distress that patients were experiencing and the difficulty that some patients had in remembering timelines,
the study coordinator was present with the patients while
they completed the questionnaire to assist with question
comprehension and to encourage patients to do their best
with memory recollection. Additional information about
the exact cancer type, site, and staging was collected from
patient charts. The TNM tumour staging followed the
7th edition of the American Joint Committee on Cancer
staging manual16.

Study Outcomes
The two primary study outcomes were these points of possible delay: time from the patient first noticing symptoms
to first presentation to a hcp (patient-related delay) and
time from first presentation to a hcp to first presentation
to the mdt clinic (provider-related delay). Those intervals
were further segmented into time between making an
appointment with a hcp and being seen, seeing a hcp to
imaging, and seeing a hcp to biopsy. We also recorded the
number of hcps that a patient saw before being referred to
the mdt clinic.
Subgroup analyses were performed to determine
whether there were associations of clinical and patient
characteristics (stage of disease, hnc site, history of smoking, history of alcohol use, living situation, age, sex, and
education) with the study outcomes already described.

Data Analysis
Study outcomes were descriptively analyzed. Frequency
statistics and means with standard deviations were calculated for patient demographics, clinical presentation,
and time intervals in the diagnostic pathway (that is, from
onset of symptoms, to time taken to make an appointment,
to diagnosis). A Pearson chi-square or Fisher exact test
(where appropriate) was conducted to compare differences
in rates of presenting symptoms, demographic and clinical
features, and patient-perceived delays in care and seeking
medical attention. The independent samples t-test or analysis of variance (where appropriate) was conducted to
compare mean differences for each subgroup on continuous study outcomes, including demographics, number
of hcps seen, and intervals in the care pathway. Data were
analyzed using the IBM SPSS Statistics software application
(version 25.0: IBM, Armonk, NY, U.S.A.). Statistical significance was determined a priori at the alpha level of 0.05.
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TABLE I

London Health Sciences Centre multidisciplinary team patient survey for referral timings

Date _____/_____/_____

Study ID number ______________

Section 1
1)

What is the reason for today’s appointment?
_____________________________________________________________________________________________________________________

Section 2
1)

Please check ALL symptoms, those that were present when you first became aware of this health problem:
o

Mouth sore

o

Trouble opening mouth

o

Stuffy nose

o

Lump in the neck

o

Trouble chewing

o

Decreased sense of smell

o

White patch

o

Trouble swallowing

o

Trouble hearing

o

Red patch

o

Pain with swallowing

o

Draining ear

o

Pain

o

Change in voice

o

Double vision

o

Bleeding

o

Trouble breathing

o

Watery eyes

o

Loose teeth

o

Headaches

o

Numbness or tingling

o

Dentures that no longer fit

o

Runny nose

o

New skin growth

o

Other ______________

A. Do you have a family doctor? o

Yes

o

No

B. When did your symptoms first occur? _____/_____/_____ (Estimate the date)
C. When did you first tell a health care provider? _____/_____/_____ (Estimate the date)
D. Who did you first discuss your symptoms with?
o

Family doctor

o

Dentist

o

Emergency

o

Walk-in clinic

o

Oral surgeon

o

Nurse

o

Other ______________

E. How long did it take you to see that health care provider? _____/_____/_____ (Estimate the date)
F. Did this health care provider examine the area of concern? o
2)

Do you think there was a delay in your care? o

Yes

3)

Did you wait in seeking medical attention for your symptoms? o

o

Yes

o

No

No
Yes

o

No

Section 3
This section will provide us with the referral process and patient pathway in diagnosis of their head and neck cancer.
Please list the specialties and the dates seen for all health care providers you have seen for the problem listed above. Health care providers
include ENT, oral surgeons, dentists, family doctors, emergency physicians, naturopaths, nurses, chiropractors, etc.
Health Care Provider 1
Specialty ______________ Month/year 1st seen _______/_______ Number of times seen _______
Health Care Provider 2
Specialty ______________ Month/year 1st seen _______/_______ Number of times seen _______
Health Care Provider 3
Specialty ______________ Month/year 1st seen _______/_______ Number of times seen _______
Health Care Provider 4
Specialty ______________ Month/year 1st seen _______/_______ Number of times seen _______
Health Care Provider 5
Specialty ______________ Month/year 1st seen _______/_______ Number of times seen _______

Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.

e469

DELAY IN DIAGNOSIS OF PATIENTS WITH HNC IN CANADA, Kassirian et al.

TABLE I

Continued

Section 4
This section will ask you some questions about smoking, alcohol intake, your employment status.
1)

Are you/have you ever been a smoker? o

Yes

o

No

A. How much do you smoke per day? Please specify packs or cigarettes. _______/day
B. How many years have you smoked for? _______ years
C. If you quit, how many years ago did you quit? _______ years
2)

How many alcoholic drinks do you have per day? Please specify what the drink is: ________ ____________________

3)

Which best describes your employment status? (Please tick one box only)

4)

o

Employed full-time

o

Unemployed (not seeking work)

o

Permanent sick/disabled

o

Employed part-time

o

Retired

o

Temporarily sick/disabled

o

Unemployed (seeking work)

o

Student

o

Looking after family/home

o

Other ______________

What is your highest education level? (Please tick one box only)
o

Degree (or equivalent)

o

High school

o

Diploma (or equivalent)

o

Did not complete high school

Section 5
This questionnaire helps your physician to know how you are feeling. Read every sentence, place an “X” on the answer that best describes
how you have been feeling during the LAST WEEK. You do not have to think too much to answer. In this questionnaire, spontaneous
answers are more important.
A I feel tense or ‘wound up’
Most of the time
A lot of the time
From time to time (occasionally)
Not at all

3
2
1
0

D I feel as if I am slowed down
Nearly all the time
Very often
Sometimes
Not at all

D I still enjoy the things I used to enjoy
Definitely as much
Not quite as much
Only a little
Hardly at all

0
1
2
3

A I get a sort of frightened feeling like “butterflies” in the stomach
Not at all
0
Occasionally
1
Quite often
2
Very often
3

A I get a sort of frightened feeling as if something awful is
about to happen

D

3
2
1
0

I have lost interest in my appearance

Definitely
I don’t take as much care as I should
I may not take quite as much care
I take just as much care

3
2
1
0

Very definitely and quite badly
Yes, but not too badly
A little, but it doesn’t worry me
Not at all

3
2
1
0

D I can laugh and see the funny side of things
As much as I always could
Not quite so much now
Definitely not so much now
Not at all

0
1
2
3

A I feel restless as I have to be on the move
Very much indeed
Quite a lot
Not very much
Not at all

3
2
1
0

A Worrying thoughts go through my mind
A great deal of the time
A lot of the time
From time to time, but not often
Only occasionally

3
2
1
0

D I look forward with enjoyment to things
As much as I ever did
Rather less than I used to
Definitely less than I used to
Hardly at all

0
1
2
3

D I feel cheerful
Not at all
Not often
Sometimes
Most of the time

3
2
1
0

A I get sudden feelings of panic
Very often indeed
Quite often
Not very often
Not at all

3
2
1
0
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TABLE I

Continued

A I can sit at ease and feel relaxed
Definitely
Usually
Not often
Not at all

D I can enjoy a good book or radio/TV program
Often
Sometimes
Not often
Very seldom

0
1
2
3

0
1
2
3

Section 6 (health care provider use only)
Type and location of patient’s cancer
_____________________________________________________________________________________________________________________
TNM staging of patient’s cancer T_______ N_______ M_______ Date of staging _____/_____/_____
Some people experience pain or discomfort for different reasons
Do you have any pain or discomfort? If yes, please explain _________________________________
Do you think your pain is controlled?
If yes, please answer the following
What does it feel like? _________________________________
What makes your pain worse? _________________________________
What makes your pain better? _________________________________
Please check if you live o alone o with spouse o with family o other ______________
Do you have any children? o Yes

o No If yes, do they live at home? ______________

What is your occupation? _______________________________________________________________
Are you worried about the impact the illness has had or may have on your financial resources?
_____________________________________________________________________________________________________________________
Onset of symptoms
Date (estimate) _____/_____/_____
Specialty:
o Family doctor

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Nurse

o Other ______________

o Nurse

o Other ______________

o Nurse

o Other ______________

o Nurse

o Other ______________

Investigations:
o Ultrasound
1st Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor
Investigations:
o Ultrasound
2nd Health care visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor
Investigations:
o Ultrasound
3rd Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor
Investigations:
o Ultrasound
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TABLE I

Continued

Section 6 (health care provider use only)
4th Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Dentist

o Oral surgeon

o Emergency

o CT scan

o MRI

o Biopsy

o Nurse

o Other ______________

o Nurse

o Other ______________

Investigations:
o Ultrasound
5th Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor
Investigations:
o Ultrasound
Investigation

Date
ordered

Date
completed

Date results
discussed

Ultrasound
CT scan
MRI
Biopsy 1
Biopsy2
Other ______________
Other ______________
Other ______________
ENT = ear, nose, throat; CT = computed tomography; MRI = magnetic resonance imaging.

RESULTS
Baseline Characteristics
Tables ii and iii summarize patient demographics and
characteristics of the malignancy. Mean age of the patients
was 67.5 years, and most patients were men (78.4%). The
most common site was the oral cavity, with squamous cell
carcinoma constituting 78.4% of the histology. There was
an even distribution of patients presenting with early- and
advanced-stage disease. In terms of smoking history, 64 patients (62.7%) had a history of smoking. The only baseline
characteristic that was significantly different between the
early-stage and advanced-stage groups was number of years
smoked: compared with individuals in the advanced-stage
group, individuals in the early-stage group had smoked for
a fewer number of years (mean: 25.6 years vs. 34.2 years;
p = 0.04). No baseline characteristics differed significantly
between the early-stage and advanced-stage groups.

Initial Presenting Symptoms
The most common presenting symptom in all patients was
a lump in the neck (38.2%); other symptoms were pain in
the primary malignancy site (24.5%), a mouth sore (20.6%),
change in voice (16.7%), and a new skin growth (14.7%).
Compared with the early-stage group, the advanced-stage
group had a higher rate of having a lump in the neck as their
presenting symptom (43.1% vs. 27.9%, p = 0.05). Otherwise,
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there were no significant differences in initial symptoms
between the early- and advanced-stage groups.

Intervals in the Care Pathway
Table iv summarizes the intervals between events in the
diagnostic pathway from symptom onset to first visit to
the mdt clinic. Mean time from symptom onset to presentation to a hcp was 3.9 months—effectively, the patientdelay interval. It took an average of 0.2 months (7.1 days) to
obtain an appointment with a hcp once contact had been
made by the patient. The time from presentation to first
hcp to the mdt appointment was 10.7 months—effectively,
the provider-delay interval. The mean time from first hcp
visit to biopsy was 9.8 months. The total time from first
onset of symptoms to presentation at the mdt clinic was
15.1 months. No correlation of any of those time intervals
with age, sex, education status, living situation, having
children, having a family doctor, history of smoking, history
of alcohol use, tumour site, or presentation with early- or
advanced-stage disease was observed (p > 0.05, Table iv).

HCPs Seen Before the MDT Clinic Appointment
The mean number of hcps seen before the appointment
at the mdt clinic was 3 (range: 1–7). More than 3 hcps had
been seen by 51% of patients with early-stage disease and
by 59.5% of patients with advanced-stage disease. No significant differences were noted in the mean number of hcps

Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.
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TABLE II Patient demographics
Characteristic

Overall

43

51

102b

Mean age (years)

68.65±12.04

68.27±11.13

67.51±11.98

0.88

Sex [n (%) men]

33 (76.7)

41 (80.4)

80 (78.4)

0.67

Employment [n (%) retired]

26 (60.5)

33 (64.7)

62 (60.8)

0.67

Education [n (%) ≥high school]

34 (79.1)

36 (70.6)

77 (75.3)

0.35

Living situation [n (%) alone]

11 (25.5)

10 (19.6)

22 (21.6)

0.49

Have children [n (%)]

31 (72.1)

40 (78.4)

76 (74.5)

0.48

Have a family doctor [n (%)]

43 (100)

46 (90.2)

96 (94.1)

0.11

Smoking status
History of smoking [n (%)]
Currently smoking [n (%)]
Mean years smoked
Mean cigarettes daily
Mean pack–years

26 (60.5)
7 (16.3)
25.60±16.43
19.90±14.12
30.35±30.90

33 (64.7)
13 (25.5)
34.19±12.22
18.23±11.70
31.41±21.17

64 (62.7)
23 (22.5)
29.97±14.43
18.41±12.53
29.73±25.23

0.53
0.55
0.04
0.63
0.88

29 (67.4)
2 (4.7)
1.92±1.60

37 (72.5)
2 (3.9)
2.38±2.08

71 (69.6)
4 (3.9)
2.10±1.85

0.72
0.86
0.42

Alcohol status
Current user [n (%)]
Previous abuse [n (%)]
Mean drinks daily
b


p
Valuea

Advanced

Patients (n)

a

Disease stage
Early

Significant values appear in boldface type.
Of 102 total patients, 8 had disease of unknown stage based on American Joint Committee on Cancer criteria.

seen before the mdt clinic visit, including by cancer stage
group (p > 0.05).

Patient Perception of Delay
Of the surveyed patients, 29% discussed their symptoms
at a routine visit with their primary hcp. A statistically significantly higher proportion of patients in the early-stage
group (41.9%) than in the advanced-stage group (15.7%)
spoke to their primary hcp about their symptoms during a
routine visit (p = 0.01). After their symptoms started, 51%
of patients delayed seeking medical care. A statistically
significant higher proportion of patients in the early-stage
group (67.4%) than in the advanced-stage group (41.2%)
waited to seek medical attention for their symptoms
(p = 0.01). A perception of a delay in their care was expressed by 55% of patients, with no difference between
the early- and advanced-stage groups (p > 0.05), and 52%
of patients expressed regret and wished that they had done
things differently to speed up their care, with no difference
between the early- and advanced-stage groups (p > 0.05).
No differences in perceived delay were associated with
education level, employment status, children, smoking or
alcohol use, or early- and advanced-stage disease (p > 0.05).
However, a significant difference with respect to waiting
to seek medical attention was noted between patients
who lived alone and those who did not (68.2% vs. 42.9%
respectively, p = 0.04).

DISCUSSION
In this study, we report that the total delay in diagnosis from
first symptom onset to presentation at our head-and-neck

Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.

clinic was 15.07 months. The greatest delay was
provider-caused delay (from first hcp encounter to presentation at the mdt clinic). On average, 50% of patients had to
see 3 hcps before presenting to the mdt clinic. We addressed
total delay in diagnosis for all hnc sites and considered a
wide variety of relevant patient- and tumour-related factors, finding no correlation of any patient or tumour factor
with delay in presentation.
The mean patient-caused delay in our study from
first symptom onset to presentation to a hcp was almost
4 months. Previous studies have demonstrated a similar
mean patient delay: 3.7–4.3 months for all hncs13,17 and
3.5–5.4 months for oral cancers18. Several studies found that
certain patient factors were associated with the interval
before first presentation to a hcp: fear, lack of pain, lack of
suspicion of cancer, smoking history, and socioeconomic
factors17,19,20. We did not find that tumour site, socioeconomic factors, or smoking history correlated with patient
delay. In the literature, findings are variable, with some
studies demonstrating a correlation between cancer site
and patient delay17,21,22 and other studies, not 20,22–24.
We did not find that stage at presentation was associated with patient delay. The association between patient
delay and stage at presentation has previously been studied
with varying results7,20,22,23. Given that our study included
patients with hnc at all sites, the presenting symptoms
and intensity of symptoms could have been quite variable,
which might account for the lack of an association. Given
that 19.6% of patients in our study had an oropharynx
cancer, which, when related to infection with the human
papillomavirus, often presents with an asymptomatic
neck mass25, the lack of correlation for site and stage of
mdt
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TABLE III Cancer characteristics
Characteristic
Early

Advanced

Overall

43

51

102a

34 (79.1)
9 (20.9)

41 (80.4)
10 (19.6)

80 (78.4)
22 (21.6)

17 (39.5)
5 (11.6)
7 (16.3)
5 (11.6)
0 (0)
1 (2.3)

12 (23.5)
14 (27.5)
3 (5.9)
6 (11.8)
4 (7.8)
1 (2.0)

31 (30.4)
20 (19.6)
13 (12.7)
11 (10.8)
4 (3.9)
2 (2)

8 (18.6)

9 (17.7)

21 (20.1)

AJCC stage
I
II
III
IV
Unknown

21 (48.8)
22 (51.2)
0 (0)
0 (0)
0 (0)

0 (0)
0 (0)
18 (35.3)
33 (64.7)
0 (0)

21 (20.6)
22 (21.6)
18 (17.6)
33 (32.4)
8 (7.8)

T Stage
T1
T2
T3
T4
Tx

20 (46.5)
21 (48.8)
2 (4.7)
0 (0)
0 (0)

7 (13.7)
14 (27.5)
10 (19.6)
20 (39.2)
0 (0)

27 (26.5)
35 (34.3)
12 (11.8)
20 (19.6)
8 (7.8)

N Stage
N0
N1
N2
N3
Nx

37 (86.0)
3 (7)
1 (2.3)
0 (0)
2 (4.7)

10 (19.6)
12 (23.5)
24 (47.1)
3 (5.9)
2 (3.9)

47 (46.1)
15 (14.7)
28 (27.5)
3 (2.9)
9 (8.8)

M Stage
M0
M1
Mx

36 (83.7)
0 (0)
7 (16.3)

41 (80.4)
2 (3.9)
8 (15.7)

77 (75.5)
2 (2)
23 (22.5)

Patients
Histology
Squamous cell carcinoma
Other
Site
Oral cavity
Oropharynx
Salivary glands
Larynx
Hypopharynx
Nasal cavity or
paranasal sinuses
Other

a

Stage [n (%)]

Of 102 total patients, 8 had disease of unknown stage based on
American Joint Committee on Cancer criteria. Of 80 patients with
squamous cell carcinoma and 22 with “other” histology, 5 and 3
respectively had disease of unknown stage.

presentation with patient delay might have been influenced
by that subgroup. A larger sample size would have allowed
for subgroup analyses by site of hnc.
The most common presenting symptom for hnc in our
cohort was a neck mass, followed by pain at the primary
cancer site and a mouth sore. Other studies have found that
the presence of a neck mass or lymphatic metastasis has
resulted in a shorter patient delay17,20,23. Pain was the second most common presenting symptom in our study. Two
studies found that pain has no effect on patient delay17,24,
and one study found a shorter patient delay for patients experiencing pain 20. In a mixed-methods study by Lee et al.,
reasons for patient delay reported by patients included a
lack of awareness of the signs and symptoms of hnc (61%
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of patients), believing that alternative medicines would
cure their disease (20% of patients), and not knowing that
smoking and alcohol could cause hnc (57% of patients)13.
Lack of awareness, education, and knowledge of the risk
factors for hnc—plus the low profile of hnc in the public
media—might all be factors contributing to patient delay
and thus deserving of further study3,20.
We did not find that sociodemographic or socioeconomic factors correlated with mean patient delay; however,
when patients were asked about their perception of delay,
patients who lived alone were more likely to delay seeking
medical attention. The finding of no correlation between
sociodemographic or socioeconomic factors and patient
delay is consistent with results in other studies17,21,23,24.
Smoking status and alcohol consumption also did not
appear to affect patient delay. Previous studies in Finland,
which has a national public health care system and allows
patients to seek medical care regardless of income, have
demonstrated that a lower socioeconomic status leads to
longer patient delays26,27.
Our study highlighted regret on the part of more than
half the patients that they did not seek attention sooner.
Addressing patient delay is more complex than simply
providing education about the risk factors for hnc , or
awareness or screening campaigns. A review by Noonan 26
about patient delay in oral cancer suggests that application
of a psychosocial theoretical model to studies in the field
of diagnostic delay should be used, because the perception
of the signs of cancer by patients might be misunderstood
and lead patients to erroneous behavioural responses that
might delay them in seeking medical attention 26.
The longest period of delay was found in the provider
interval: almost 11 months from the first hcp visit to the
first mdt clinic visit. It is worth noting that this particular
delay interval is variably defined in the literature. Some
publications describe physician delay as the interval from
first hcp visit to date of diagnosis (biopsy date)19 ; others
describe diagnostic delay as the time from referral by a
hcp to the final treatment decision by a multidisciplinary
tumour conference22. We chose to define provider delay as
the time from first hcp presentation to presentation at the
mdt clinic so as to ensure that the entire time from first
contact with a hcp until the treatment decision was made
in the mdt clinic was included.
In Ontario, regionalization of hnc care has resulted
in all patients with hnc being treated at a small number of
high-volume hnc centres. In the past, patients might have
been treated by community head-and-neck surgeons or
radiation oncologists working in smaller centres, but today’s patients might first have to be seen by a community
otolaryngologist or oral surgeon for diagnosis. They are
then referred to the regional hnc treatment centre. We
hypothesized that the new pathway might result in longer
provider delays and multiple hcp referrals. We found that
the provider delay was substantially longer than the delay
that has been reported in the literature. The mean provider
delay in our study was 11 months. A previous study conducted in Ontario in 2016 demonstrated a mean provider delay
of 8.3 months—although the patients in that study were
seen by a head-and-neck surgeon and not at a mdt clinic13.
Other studies have demonstrated shorter provider delays
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TABLE IV Intervals for diagnostic pathway events from symptom onset to first multidisciplinary team (MDT) visit
Event
From

Mean interval (months), by stage
To

Early

Advanced

Overall

First symptom onset

1st HCP

visita

5.51±16.09

2.03±3.83

3.93±11.71

0.18

Appointment made

1st HCP visit

0.17±0.35

0.31±0.61

0.23±0.50

0.18

First HCP visit

Imaging (US, CT, and MRI)

9.39±20.60

6.43±11.77

8.12±16.19

0.41

First HCP visit

Biopsy

10.73±22.99

8.21±13.79

9.83±18.27

0.60

First symptom onset

MDT visit

16.23±27.73

10.27±14.19

15.07±31.54

0.21

First HCP visit

MDT visit

10.95±20.04

8.04±12.59

10.74±20.00

0.39

HCPs seen

p Value

Patients [n (%)]

<3

17 (40.5)

25 (49.0)

45 (44.1)

0.41

≥3

25 (59.5)

26 (51.0)

56 (54.9)

0.41

a

Most common first HCP seen was a family doctor (69.6% of total). Most common second, third, fourth, and fifth HCP seen was an otolaryngologist outside of the MDT clinic.
HCP = health care practitioner; US = ultrasonography; CT = computed tomography; MRI = magnetic resonance imaging.

outside of the Canadian health care system: approximately
3–5 months in the United Kingdom and 3 months in the
United States3,6,7.
Although we did not examine whether provider delays
have become longer since the regionalization of hnc care,
regionalization might have contributed to a longer delay in
our study than in others. We also found that patients saw
a mean of 3 hcps (range: 1–7) before being seen at the mdt
clinic. Although the provider delay in our study did not
affect stage at presentation, a mean delay of 11 months,
with several referrals to hcps, is undoubtedly prolonged and
unacceptable. That length of delay could lead to increased
patient anxiety and lack of trust in the health care system,
with more than half the patients in our study experiencing
regret and stating that they wished they had done things
differently. Although treatment at high-volume head-andneck cancer centres has been shown to lead to improved
outcomes for patients28,29, the effect that regionalization
has had on diagnostic delay and patient care has not been
thoroughly studied. We demonstrated that significant improvement could be made in provider delay in that regard.
Several components of the interval between first presentation to a hcp and the mdt clinic visit could have contributed to provider delay. Lack of a family doctor or poor access
to a family doctor might have contributed, given that 30%
of the patients in the present study presented to a hcp other
than their family doctor. Provider education about the signs
and symptoms of hnc might have contributed to provider
delay, given that almost 40% of patients presented with a
neck mass, which might have been interpreted by hcps as
having an infectious cause. Further, only 22% of patients
were current smokers, which is a common risk factor for
hnc and might have resulted in a lower suspicion of hnc
by the hcp. The diagnostic workup and referral process
might also have contributed to provider delay, including
wait times for imaging, biopsy, and specialist referrals.
A previous Canadian study identified lack of physician
knowledge as a theme related to provider delay, identifying 3 subthemes, including inappropriate prescription
of medications for infection or gastroesophageal reflux
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disease, lack of knowledge about the signs and symptoms
of hnc, and inappropriate reassurance of good heath by
hcp s13. Provider delay was longer than patient delay in
our study, suggesting that the more effective intervention
might be to focus first on shortening the total diagnostic
delay. Possible ways to shorten provider delay include
improving training for physicians and dentists about the
signs and symptoms of hnc, providing continuing medical
education about hnc, targeting dentists (who represented a
significant proportion of the hcps in our study), and streamlining the referral process so that patients avoid multiple
referrals. Studies assessing educational programs or tools
for physicians-in-training would be very useful.
The strengths of our study lie in the complete characterization of each patient’s pathway to the mdt clinic. Previous studies have defined provider delay as the interval from
first contact with a hcp to the date of diagnosis. However, in
the health care system today, treatment decisions are not
made until the patient is seen at the mdt clinic, and patients
could experience further delay while waiting for imaging
and referral to the mdt clinic. Other strengths include
our description of the numbers and types of hcps seen,
the timing of patient appointments, and the perception
of patients about their diagnostic care pathway. Furthermore, all those factors are viewed from the perspective of
the Canadian health care system, eliminating some of the
socioeconomic barriers that are a factor in other countries.
Studies conducted in health care systems outside of Canada do not detail as many intervals in appointments and
do not specify which hcps were seen19,30,31. Furthermore,
our study is prospective; other studies that have looked
at similar data have been significantly affected by recall
bias because of their retrospective design. Although recall bias remains an issue in the present study because
of patient reporting, the prospective design reduces the
effect. We tried to minimize recall bias by having patients
complete the questionnaire during their first encounter at
the mdt clinic. We also included all hnc sites and analyzed
delay as a continuous variable. Certain studies have focused on the oral cavity alone and have therefore focused
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on the diagnostic sensitivity of hcps with respect to lesions
of the oral cavity4,31,32. However, many other symptoms,
such as neck lumps, can be just as easily misdiagnosed
or overlooked. Finally, we developed a survey based on a
previously validated survey. We assisted patients in completing the survey, and we recruited consecutive patients.
Our study is limited in a number of ways. The first
limitation is recall bias. Patients were asked to recall their
awareness of their symptoms and their contact with hcps,
both of which can be influenced by inaccurate recall. We
attempted to mitigate that limitation with a prospective design and a survey that was created to be as clear as possible,
with precise instructions. However, we were not able to
determine how accurate were the patient’s responses about
the delay experienced. The questionnaire was administered after the cancer diagnosis, during a stressful medical appointment in which patients were being informed
of their treatment options. That environment might have
affected the ability to accurately recall onset of symptoms,
potentially leading to a falsely reconstructed sequence of
events, given that the outcome was known to the patient.
Further, the recall bias could have varied depending on the
patient’s symptoms, because some symptoms might have
been more prominent than others. Patients-reported data
concerning the duration of their symptoms are subjective and might have been underestimated, given that the
patients were aware of the cancer diagnosis.
A second issue is the small sample size, which might
have resulted in associations not being observed. In addition, only 22% of our sample were current smokers; the
proportion of smokers in similar studies tends to be significantly higher, indicating that our sample might not be
completely representative22,23.
Yet another limitation, particularly relevant to the
Canadian health care system and cancer care in Ontario,
is that we did not consider distance traveled and economic limitations. The number of designated hnc sites within
the regional model in Ontario is small, which can lead to
patients having to travel long distances for care.

CONCLUSIONS
We observed a significant duration of diagnostic delay,
with the greatest delay being experienced as provider
delay. Whether the observed lengthened intervals in the
diagnostic timeline affect patient outcomes is still unclear.
Certain measures could be taken to shorten the diagnostic delay, including educating hcps and streamlining the
referral process in the era of regionalization of hnc care.
Future research should explore the efficacy of such interventions, and ultimately, whether those interventions
result in improved outcomes.
CONFLICT OF INTEREST DISCLOSURES
We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
AUTHOR AFFILIATIONS
*Department of Medicine and †Department of Otolaryngology,
Schulich School of Medicine and Dentistry, Western University,
London Health Sciences Centre, London, ON; ‡Department of
Otolaryngology, Moffitt Cancer Center and Research Institute,

e476

University of South Florida, Tampa, FL, U.S.A.; § Department of
Radiation Oncology, Schulich School of Medicine and Dentistry,
Western University, London Health Sciences Centre, London, ON.
REFERENCES
1. Canadian Cancer Statistics Advisory Committee. Canadian
Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society;
2019.
2. Wheless SA, McKinney KA, Zanation AM. A prospective study
of the clinical impact of a multidisciplinary head and neck
tumor board. Otolaryngol Head Neck Surg 2010;143:650–4.
3. Patel UA, Brennan TE. Disparities in head and neck cancer:
assessing delay in treatment initiation. Laryngoscope 2012;
122:1756–60.
4. Chiou SJ, Lin W, Hsieh CJ. Assessment of duration until
initial treatment and its determining factors among newly
diagnosed oral cancer patients. Medicine (Baltimore) 2016;
95:e5632.
5. Mundi N, Theurer J, Warner A, et al. The impact of seasonal
operating room closures on wait times for oral cancer surgery.
Curr Oncol 2018;25:67–72.
6. McGurk M, Chan C, Jones J, O’Regan E, Sherriff M. Delay in
diagnosis and its effect on outcome in head and neck cancer.
Br J Oral Maxillofac Surg 2005;43:281–4.
7. Goy J, Hall SF, Feldman-Stewart D, Groome PA. Diagnostic
delay and disease stage in head and neck cancer: a systematic
review. Laryngoscope 2009;119:889–98.
8. Seoane J, Takkouche B, Varela-Centelles P, Tomás I, SeoaneRomero JM. Impact of delay in diagnosis on survival to head
and neck carcinomas: a systematic review with meta-analysis.
Clin Otolaryngol 2012;37:99–106.
9. Murphy CT, Galloway TJ, Handorf EA, et al. Survival impact
of increasing time to treatment initiation for patients with
head and neck cancer in the United States. J Clin Oncol 2016;
34:169–78.
10. Felippu AWD, Freire EC, de Arruda Silva R, Guimarães AV,
Dedivitis RA. Impact of delay in the diagnosis and treatment of
head and neck cancer. Braz J Otorhinolaryngol 2016;82:140–3.
11. Health Quality Ontario (hqo). Time from decision to having
cancer surgery [Web resource]. Toronto, ON: hqo; 2020. [Available at: https://www.hqontario.ca/system-performance/waittimes-for-surgeries-and-procedures/wait-times-for-cancersurgeries/time-from-decision-to-having-cancer-surgery
(select Head and Neck Cancers); cited 28 February 2020]
12. Ontario Health (Cancer Care Ontario) [oh(cco)]. Radiation
Treatment Program: Implementation Plan 2019–2023 [Web
page]. Toronto, ON: oh(cco); 2018. [Available at: https://www.
cancercareontario.ca/en/cancer-care-ontario/programs/
clinical-services/radiation-treatment/implementation-plan
#:~:tex t= Ca ncer %20Ca re%20Onta r io’s%20ta rget%20
wait,80%25%20in%202017%2F2018; cited 21 September 2020]
13. Lee JJ, Dhepnorrarat C, Nyhof-Young J, Witterick I. Investigating
patient and physician delays in the diagnosis of head and neck
cancers: a Canadian perspective. J Cancer Educ 2016;31:8–14.
14. Yu T, Wood RE, Tenenbaum HC. Delays in diagnosis of head
and neck cancers. J Can Dent Assoc 2008;74:61.
15. Neal RD, Nafees S, Pasterfield D, et al. Patient-reported measurement of time to diagnosis in cancer: development of the
Cancer Symptom Interval Measure (c-sim) and randomised
controlled trial of method of delivery. BMC Health Serv Res
2014;14:3.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti
A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY:
Springer–Verlag; 2009.
17. Nieminen M, Aro K, Jouhi L, Back L, Makitie A, Atula T. Causes for delay before specialist consultation in head and neck
cancer. Acta Oncol 2018;57:1677–86.

Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.

DELAY IN DIAGNOSIS OF PATIENTS WITH HNC IN CANADA, Kassirian et al.
18. Stefanuto P, Doucet JC, Robertson C. Delays in treatment of
oral cancer: a review of the current literature. Oral Surg Oral
Med Oral Pathol Oral Radiol 2014;117:424–9.
19. Nash R, Hughes J, Sandison A, Stewart S, Clarke P, Mace A.
Factors associated with delays in head and neck cancer treatment: case–control study. J Laryngol Otol 2015;129:383–5.
20. Väisänen JA, Syrjälä AMH, Pesonen PRO, Pukkila MJ, Koivunen
PT, Alho OP. Characteristics and medical-care-seeking of
head and neck cancer patients: a population-based crosssectional survey. Oral Oncol 2014;50:740–5.
21. Rogers SN, Pabla R, McSorley A, Lowe D, Brown JS, Vaughhan
ED. An assessment of deprivation as a factor in the delays in
presentation, diagnosis and treatment in patients with oral
and oropharyngeal squamous cell carcinoma. Oral Oncol
2007;43:648–55.
22. Brouha XDR, Tromp DM, Koole R, Hordijk GJ, Winnubst JAM,
de Leeuw JRJ. Professional delay in head and neck cancer
patients: analysis of the diagnostic pathway. Oral Oncol
2007;43:551–6.
23. Koivunen P, Rantala N, Hyrynkangas K, Jokinen K, Alho OP.
The impact of patient and professional diagnostic delays on
survival in pharyngeal cancer. Cancer 2001;92:2885–91.
24. Amir Z, Kwan SY, Landes D, Feber T, Williams SA. Diagnostic
delays in head and neck cancers. Eur J Cancer Care (Engl) 1999;
8:198–203.
25. Berman TA, Schiller JT. Human papillomavirus in cervical
cancer and oropharyngeal cancer: one cause, two diseases.
Cancer 2017;123:2219–29.

Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.

26. Noonan B. Understanding the reasons why patients delay
seeking treatment for oral cancer symptoms from a primary
health care professional: an integrative literature review. Eur
J Oncol Nurs 2014;18:118–24.
27. Akram M, Siddiqui SA, Karimi AM. Patient related factors
associated with delayed reporting in oral cavity and oropharyngeal cancer. Int J Prev Med 2014;5:915–19.
28. Gourin CG, Stewart CM, Frick KD, et al. Association of hospital volume with laryngectomy outcomes in patients with
larynx cancer. JAMA Otolaryngol Head Neck Surg 2019;145:
62–70.
29. Lin DJ, McConkey CC, Nankivell P, Dunn J, Mehanna H. The
impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and
neck cancer: an analysis of the pet-neck trial outcomes, ukcrn
portfolio, and Hospital Episode Statistics ( hes) in England.
Oral Oncol 2018;85:40–3.
30. Azhar N, Doss JG. Health-seeking behaviour and delayed
presentation of oral cancer patients in a developing country:
a qualitative study based on the self-regulatory model. Asian
Pac J Cancer Prev 2018;19:2935–41.
31. Wang KH, Song BH, Gilde JE, et al. Diagnostic pathway of
oral cavity cancer in an integrated health care system. Perm J
2018;22:17–152.
32. Liao CT, Chen HN, Wen YW, et al. Association between the
diagnosis-to-treatment interval and overall survival in Taiwanese patients with oral cavity squamous cell carcinoma.
Eur J Cancer 2017;72:226–34.

e477

